Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study
Australasian Journal of Dermatology · 2025
DOI: 10.1111/ajd.14573 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Francisco Javier Melgosa Ramos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Neoplasms, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Managing moderate‐to‐severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real‐world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation. After 52 weeks of follow‐up, guselkumab achieved sustained clinical improvement in skin and joint symptoms, with no observed cases of cancer progression or recurrence. Two patients developed new malignancies during treatment, but guselkumab was not discontinued. These findings support the use of IL‐23 inhibitors as a safe therapeutic option in this complex patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain.
- Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain.
- Department of Dermatology, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain.
- Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain.
- Department of Dermatology, Consorcio Hospital General Universitario, Valencia, Spain.
- Department of Dermatology, Hospital Vega Baja, Orihuela, Alicante, Spain.
ORCID-Profile: Francisco Javier Melgosa Ramos, Antonio Martorell, Jorge Magdaleno Tapial
Zitieren
APA
Melgosa Ramos, F. J., Alarcón, S. S., Puchades, A. M., Romero, I. B., Pastor, G. M. P., Apetrei, L. S., Díaz, F. J. M., Martorell, A., Pastor, M. V., Salvador, J. M. O., Torralba, A. S., Galarreta Pascual, M., & Magdaleno Tapial, J. (2025). Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14573
Vancouver
Melgosa Ramos FJ, Alarcón SS, Puchades AM, Romero IB, Pastor GMP, Apetrei LS, et al. Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14573
BibTeX
@article{MelgosaRamos2025,
author = {Melgosa Ramos, Francisco Javier and Alarcón, Sergio Santos and Puchades, Almudena Mateu and Romero, Isabel Belinchón and Pastor, Gemma Mª Pérez and Apetrei, Luca Schneller-Pavelescu and Díaz, Francisco Javier Mataix and Martorell, Antonio and Pastor, Manel Velasco and Salvador, José María Ortíz and Torralba, Antonio Sahuquillo and Galarreta Pascual, Marta and Magdaleno Tapial, Jorge},
title = {Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study},
journal = {Australasian Journal of Dermatology},
year = {2025},
doi = {10.1111/ajd.14573}
}
EUVIMED